Eli Lilly and Co (LLY) was Reiterated by Leerink Partners to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 101 from a previous price target of $96 . Leerink Partners advised their investors in a research report released on May 2, 2016.
Many Wall Street Analysts have commented on Eli Lilly and Co. Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.
On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.
Eli Lilly and Co opened for trading at $76.52 and hit $77.16 on the upside on Wednesday, eventually ending the session at $76.51, with a gain of 0.31% or 0.24 points. The heightened volatility saw the trading volume jump to 36,90,949 shares. Company has a market cap of $84,627 M.
In a different news, on Apr 28, 2016, Alfonso G Zulueta (SVP& Pres., Emerging Markets) sold 12,000 shares at $76.27 per share price. According to the SEC, on Feb 8, 2016, Stephen F Fry (SVP, HR & Diversity) sold 15,230 shares at $78.87 per share price. On Feb 3, 2016, Jackson P Tai (director) purchased 3,170 shares at $78.62 per share price, according to the Form-4 filing with the securities and exchange commission.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.